AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 17985384 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose intracoronary adenosine
Number of subjects: 51
Study 16131694 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% CHO
Number of subjects: 5
Study 16131694 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% CHO
Number of subjects: 5
Study 16131694 — intervention group
Group type: COMPARATOR
Intervention: Water placebo (WP)
Number of subjects: 5
Study 12377914 — intervention group
Group type: EXPERIMENTAL
Intervention: Cemented Mallory‐Head total hip prosthesis
Number of subjects: 250
Study 12377914 — intervention group
Group type: COMPARATOR
Intervention: Cementless Mallory‐Head total hip prosthesis
Number of subjects: 250
Study 12377914 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Cemented and Cementless)
Number of subjects: 250
Study 10418906 — intervention group
Group type: EXPERIMENTAL
Intervention: Intradermal Mycobacterium vaccae vaccine (MV)
Number of subjects: 35
Study 10418906 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine (HBV)
Number of subjects: 35
Study 7473472 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort (24 mg daily or 48 mg alternate day)
Number of subjects: 31
Study 7473472 — intervention group
Group type: COMPARATOR
Intervention: 6‐methylprednisolone (16 mg daily or 32 mg alternate day)
Number of subjects: 31
Study 7473472 — intervention group
Group type: EXPERIMENTAL
Intervention: Deflazacort
Number of subjects: 31
Study 7473472 — intervention group
Group type: COMPARATOR
Intervention: 6‐methylprednisolone
Number of subjects: 31
Study 7473472 — intervention group
Group type: EXPERIMENTAL
Intervention: Both interventions
Number of subjects: 31
Study 2290600 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimesulide (2 suppositories a day for 7 days)
Number of subjects: 100
Study 2290600 — intervention group
Group type: COMPARATOR
Intervention: Flurbiprofen (2 suppositories a day for 7 days)
Number of subjects: 100
Study 471857 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. domperidone (0.35 and 0.7 mg/kg)
Number of subjects: 59
Study 471857 — intervention group
Group type: EXPERIMENTAL
Intervention: i.v. or oral domperidone
Number of subjects: 59
Study 30763673 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy (n=25)
Number of subjects: 44
Study 30763673 — intervention group
Group type: COMPARATOR
Intervention: Progressive muscle relaxation (PMR) (n=19)
Number of subjects: 44
Study 30763673 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy
Number of subjects: 44
Study 27803094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole (6.5-8.0 mg/kg/d for 28 days)
Number of subjects: 53
Study 27803094 — intervention group
Group type: COMPARATOR
Intervention: Sbv (20 mg/kg/d for 20 days)
Number of subjects: 53
Study 27803094 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluconazole
Number of subjects: 53
Study 27803094 — intervention group
Group type: COMPARATOR
Intervention: Sbv
Number of subjects: 53
Study 26474988 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinic-based individual outpatient rehabilitative exercise during 12 weeks
Number of subjects: 240
Study 26474988 — intervention group
Group type: EXPERIMENTAL
Intervention: Community-based group exercise classes during 12 weeks
Number of subjects: 240
Study 26474988 — intervention group
Group type: COMPARATOR
Intervention: Usual medical care (wait-listed control group)
Number of subjects: 240
Study 24127141 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP
Number of subjects: 812
Study 24127141 — intervention group
Group type: COMPARATOR
Intervention: Sham CPAP
Number of subjects: 812
Study 24127141 — intervention group
Group type: EXPERIMENTAL
Intervention: CPAP (≥ 4 h per night on ≥ 70% of nights)
Number of subjects: 812
Study 24127141 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherent CPAP participants
Number of subjects: 812
Study 21792663 — intervention group
Group type: EXPERIMENTAL
Intervention: Narrow-band imaging (NBI)
Number of subjects: 78
Study 21792663 — intervention group
Group type: COMPARATOR
Intervention: White light imaging (WLI)
Number of subjects: 78
Study 21088401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing proximal lesions
Number of subjects: 91
Study 21088401 — intervention group
Group type: COMPARATOR
Intervention: Flossing instructions (control)
Number of subjects: 91
Study 21088401 — intervention group
Group type: EXPERIMENTAL
Intervention: Sealing technique
Number of subjects: 91
Study 21088401 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants' behaviour and pain perception
Number of subjects: 91
Study 17989534 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy for 3 years
Number of subjects: 0
Study 17989534 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific immunotherapy
Number of subjects: 0
Study 15101068 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self‐help (self‐help manual with a maximum of 18 short weekly visits)
Number of subjects: 81
Study 15101068 — intervention group
Group type: COMPARATOR
Intervention: Cognitive-behavioral group therapy (CBT) (18 weekly 1.5‐h sessions)
Number of subjects: 81
Study 15101068 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatment conditions
Number of subjects: 81
Study 11594446 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF)
Number of subjects: 9
Study 11594446 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PL)
Number of subjects: 9
Study 11594446 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) and Cold exposure
Number of subjects: 9
Study 9677215 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline (alone or in combination with levodopa)
Number of subjects: 12621
Study 9677215 — intervention group
Group type: EXPERIMENTAL
Intervention: Selegiline alone
Number of subjects: 12621
Study 9677215 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12621
Study 7803638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin plus doxycycline
Number of subjects: 292
Study 7803638 — intervention group
Group type: EXPERIMENTAL
Intervention: Clindamycin plus gentamicin
Number of subjects: 292
Study 7803638 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotetan plus doxycycline
Number of subjects: 292
Study 3417081 — intervention group
Group type: EXPERIMENTAL
Intervention: D-xylose test (enteral or parenteral route)
Number of subjects: 9
Study 3417081 — intervention group
Group type: COMPARATOR
Intervention: Healthy volunteers (control group)
Number of subjects: 9
Study 31469238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab at 8 mg/kg/month
Number of subjects: 3080
Study 31469238 — intervention group
Group type: COMPARATOR
Intervention: Etanercept at 50 mg/week
Number of subjects: 3080
Study 31469238 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 3080
Study 29072043 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment with Mollii® (transcutaneous electrical stimulation)
Number of subjects: 31
Study 29072043 — intervention group
Group type: COMPARATOR
Intervention: Non-active treatment (placebo)
Number of subjects: 31
Study 27324883 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (sulfur bath) combined with home exercise therapy for 3 weeks (15 occasions)
Number of subjects: 41
Study 27324883 — intervention group
Group type: COMPARATOR
Intervention: Home exercise therapy alone
Number of subjects: 41
Study 27324883 — intervention group
Group type: EXPERIMENTAL
Intervention: Balneotherapy (sulfur bath) combined with home exercise therapy
Number of subjects: 41
Study 23985088 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive emotion regulation group therapy (ERGT)
Number of subjects: 61
Study 23985088 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 61
Study 22829293 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient information leaflet
Number of subjects: 400
Study 20046519 — intervention group
Group type: COMPARATOR
Intervention: ondansetron 8 mg (group O)
Number of subjects: 98
Study 20046519 — intervention group
Group type: EXPERIMENTAL
Intervention: azasetron 10 mg (group A)
Number of subjects: 98
Study 19027322 — intervention group
Group type: EXPERIMENTAL
Intervention: ATT+Dzherelo
Number of subjects: 60
Study 19027322 — intervention group
Group type: EXPERIMENTAL
Intervention: ATT+Dzherelo+Anemin
Number of subjects: 60
Study 19027322 — intervention group
Group type: COMPARATOR
Intervention: ATT
Number of subjects: 60
Study 19027322 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatment arms
Number of subjects: 60
Study 16163908 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hypochlorite denture soak
Number of subjects: 60
Study 16163908 — intervention group
Group type: EXPERIMENTAL
Intervention: Microwaving
Number of subjects: 60
Study 16163908 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study 12577128 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid supplementation (0.4 mg/day for all women, 4 mg/day for women with a previous infant with a neural tube defect)
Number of subjects: 0
Study 12577128 — intervention group
Group type: EXPERIMENTAL
Intervention: Mandatory fortification of certain foods with folate
Number of subjects: 0
Study 10577620 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH agonist (buserelin) 100 microg intranasally once daily for two months
Number of subjects: 27
Study 10577620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 8549037 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (100 mg)
Number of subjects: 8
Study 8549037 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (10 mg)
Number of subjects: 8
Study 8549037 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 1863900 — intervention group
Group type: EXPERIMENTAL
Intervention: Long-term immunotherapy (more than 2 years)
Number of subjects: 0
Study 1863900 — intervention group
Group type: COMPARATOR
Intervention: Short-term immunotherapy (less than 1 year)
Number of subjects: 0
Study 1863900 — intervention group
Group type: COMPARATOR
Intervention: Non-allergic controls
Number of subjects: 0
Study 1863900 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (general)
Number of subjects: 0
Study 6309461 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg enalapril once daily
Number of subjects: 23
Study 6309461 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg enalapril twice daily
Number of subjects: 23
Study 6309461 — intervention group
Group type: COMPARATOR
Intervention: Placebo twice daily
Number of subjects: 23
Study 31771921 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher protein diet (1.2 g protein/kg BW)
Number of subjects: 80
Study 31771921 — intervention group
Group type: COMPARATOR
Intervention: Recommended Daily Allowance level of protein (0.8 g protein/kg BW)
Number of subjects: 80
Study 29023803 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir (TDF) therapy for 384 weeks
Number of subjects: 266
Study 29023803 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg decline ≥2.2 log10 PEIU/mL at week 24
Number of subjects: 266
Study 29023803 — intervention group
Group type: EXPERIMENTAL
Intervention: HBeAg decline at week 24
Number of subjects: 266
Study 26864371 — intervention group
Group type: EXPERIMENTAL
Intervention: Concord grape juice (CGJ) - 12 ounces (355 mL) daily for 12 weeks
Number of subjects: 25
Study 26864371 — intervention group
Group type: COMPARATOR
Intervention: Placebo - energy-, taste-, and appearance-matched, daily for 12 weeks
Number of subjects: 25
Study 25051174 — intervention group
Group type: EXPERIMENTAL
Intervention: Resveratrol
Number of subjects: 13
Study 25051174 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 21960535 — intervention group
Group type: EXPERIMENTAL
Intervention: Levosimendan (40 μg/kg bolus followed by 0.1/0.2 μg/kg/min continuous infusion)
Number of subjects: 30
Study 21960535 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 20621736 — intervention group
Group type: EXPERIMENTAL
Intervention: guaiac-based faecal occult blood test (gFOBT)
Number of subjects: 1984
Study 20621736 — intervention group
Group type: EXPERIMENTAL
Intervention: faecal immunochemical test (FIT)
Number of subjects: 1984
Study 20621736 — intervention group
Group type: EXPERIMENTAL
Intervention: flexible sigmoidoscopy (FS)
Number of subjects: 1984
Study 20621736 — intervention group
Group type: COMPARATOR
Intervention: gFOBT
Number of subjects: 1984
Study 20621736 — intervention group
Group type: COMPARATOR
Intervention: FIT
Number of subjects: 1984
Study 20621736 — intervention group
Group type: COMPARATOR
Intervention: FS
Number of subjects: 1984
Study 17641847 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 0.2 U/(kg . d)
Number of subjects: 45
Study 17641847 — intervention group
Group type: EXPERIMENTAL
Intervention: rhGH 0.4 U/(kg . d)
Number of subjects: 45
Study 17641847 — intervention group
Group type: COMPARATOR
Intervention: Control group (resting group)
Number of subjects: 45
Study 15251163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy followed by completion axillary lymph node dissection (CALND)
Number of subjects: 618
Study 15251163 — intervention group
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy followed by CALND
Number of subjects: 618
Study 11231941 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib, 50 mg once daily for 5 days
Number of subjects: 24
Study 11231941 — intervention group
Group type: EXPERIMENTAL
Intervention: Naproxen, 500 mg twice daily for 5 days
Number of subjects: 24
Study 9685462 — intervention group
Group type: EXPERIMENTAL
Intervention: Kangaroo Mother Care (KMC)
Number of subjects: 488
Study 9685462 — intervention group
Group type: COMPARATOR
Intervention: Traditional Care (TC)
Number of subjects: 488
Study 8614706 — intervention group
Group type: EXPERIMENTAL
Intervention: flesinoxan (5-HT1A agonist)
Number of subjects: 30
Study 2670798 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation technique (TM)
Number of subjects: 83
Study 2670798 — intervention group
Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PR)
Number of subjects: 83
Study 2670798 — intervention group
Group type: COMPARATOR
Intervention: Cognitive‐behavioral strategies (C)
Number of subjects: 83
Study 1002852 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapy for /s/‐defective children, 1 hour per week for 5 weeks.
Number of subjects: 10
Study 1002852 — intervention group
Group type: COMPARATOR
Intervention: No therapy (control group).
Number of subjects: 10
Study 29471855 — intervention group
Group type: EXPERIMENTAL
Intervention: 16 sessions of eye movement desensitization and reprocessing (EMDR) therapy preceded by a stabilization phase (8 sessions of Skills Training in Affect and Interpersonal Regulation (STAIR))
Number of subjects: 122
Study 29471855 — intervention group
Group type: COMPARATOR
Intervention: 16 sessions of EMDR therapy
Number of subjects: 122
Study 26656770 — intervention group
Group type: EXPERIMENTAL
Intervention: Paced Auditory Serial Addition Test (PASAT) during airway management tasks
Number of subjects: 150
Study 26656770 — intervention group
Group type: COMPARATOR
Intervention: Airway management tasks without PASAT
Number of subjects: 150
Study 24637663 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic menthol capsule treatment
Number of subjects: 8
Study 24637663 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 8
Study 23123230 — intervention group
Group type: EXPERIMENTAL
Intervention: Flurizan (a γ‐secretase modulator)
Number of subjects: 14
Study 23123230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 23123230 — intervention group
Group type: EXPERIMENTAL
Intervention: HBCP analysis
Number of subjects: 14
Study 23123230 — intervention group
Group type: COMPARATOR
Intervention: Original ADAS‐Cog analysis
Number of subjects: 14
Study 19626632 — intervention group
Group type: EXPERIMENTAL
Intervention: (11)C-tyrosine PET
Number of subjects: 27
Study 19626632 — intervention group
Group type: COMPARATOR
Intervention: (18)F-FDG PET
Number of subjects: 27
Study 19105409 — intervention group
Group type: EXPERIMENTAL
Intervention: Mildronate (1 g/day) with basic anti‐diabetic treatment and alpha‐lipoic acid for 3 months
Number of subjects: 70
Study 19105409 — intervention group
Group type: COMPARATOR
Intervention: Control group received basic anti‐diabetic treatment and alpha‐lipoic acid without mildronate
Number of subjects: 70
Study 15355135 — intervention group
Group type: EXPERIMENTAL
Intervention: ATRIUM model (attention to rules and instances in a unified model)
Number of subjects: 0
Study 15355135 — intervention group
Group type: COMPARATOR
Intervention: Exemplar model (attentional learning covering map)
Number of subjects: 0
Study 12066703 — intervention group
Group type: EXPERIMENTAL
Intervention: Glass-ionomer cement (GIC)
Number of subjects: 0
Study 12066703 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass-ionomer cement (RM-GIC)
Number of subjects: 0
Study 12066703 — intervention group
Group type: EXPERIMENTAL
Intervention: Compomer (Comp)
Number of subjects: 0
Study 12066703 — intervention group
Group type: COMPARATOR
Intervention: Composite resin (CR)
Number of subjects: 0
Study 9434659 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxybutynin hydrochloride (5 and 10 mg)
Number of subjects: 12
Study 9434659 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine hydrochloride (50 mg)
Number of subjects: 12
Study 9434659 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 8983936 — intervention group
Group type: EXPERIMENTAL
Intervention: New tablet formulation of carbamazepine (400 mg single oral dose)
Number of subjects: 9
Study 2675433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel (3 mm rod introduced four hours prior to abortion)
Number of subjects: 30
Study 2675433 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 30
Study 2675433 — intervention group
Group type: EXPERIMENTAL
Intervention: Lamicel
Number of subjects: 30
Study 2675433 — intervention group
Group type: COMPARATOR
Intervention: Lamicel and Control
Number of subjects: 30
Study 1101046 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 89
Study 1101046 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 89
Study 31337743 — intervention group
Group type: EXPERIMENTAL
Intervention: Diaphragmatic release technique
Number of subjects: 60
Study 31337743 — intervention group
Group type: EXPERIMENTAL
Intervention: Thoracic lymphatic pump technique
Number of subjects: 60
Study 31337743 — intervention group
Group type: COMPARATOR
Intervention: Conventional respiratory retraining
Number of subjects: 60
Study 27687820 — intervention group
Group type: EXPERIMENTAL
Intervention: Solifenacin (5mg, titrated to optimum dose)
Number of subjects: 0
Study 27687820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 26041365 — intervention group
Group type: EXPERIMENTAL
Intervention: Patterned feeding experience
Number of subjects: 120
Study 26041365 — intervention group
Group type: COMPARATOR
Intervention: Usual feeding care experience
Number of subjects: 120
Study 23582415 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical nitroglycerin and lidocaine
Number of subjects: 86
Study 23582415 — intervention group
Group type: COMPARATOR
Intervention: Placebo ointment
Number of subjects: 86
Study 27678225 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% chlorhexidine mouth rinse
Number of subjects: 50
Study 27678225 — intervention group
Group type: COMPARATOR
Intervention: Magnetized water (72 hours of magnetization) rinsing for 3 minutes
Number of subjects: 50
Study 27678225 — intervention group
Group type: COMPARATOR
Intervention: Magnetized water (24 hours of magnetization) rinsing for 1 minute
Number of subjects: 50
Study 27678225 — intervention group
Group type: COMPARATOR
Intervention: Magnetized water (24 hours of magnetization) rinsing for 3 minutes
Number of subjects: 50
Study 19696808 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoramic radiography
Number of subjects: 84
Study 16451859 — intervention group
Group type: EXPERIMENTAL
Intervention: Bathers (exposed to water with levels above NOAELs)
Number of subjects: 2196
Study 16451859 — intervention group
Group type: EXPERIMENTAL
Intervention: Swallowing water (as part of bathing)
Number of subjects: 2196
Study 16451859 — intervention group
Group type: EXPERIMENTAL
Intervention: Water quality standards based on NOAELs
Number of subjects: 2196
Study 16451859 — intervention group
Group type: COMPARATOR
Intervention: Current WHO recommendations
Number of subjects: 2196
Study 14738830 — intervention group
Group type: EXPERIMENTAL
Intervention: Whitening gel containing 6% hydrogen peroxide
Number of subjects: 117
Study 14738830 — intervention group
Group type: COMPARATOR
Intervention: Standard fluoride toothpaste
Number of subjects: 117
Study 11404532 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug therapy (zidovudine 300 mg or 200 mg for body weight <60 kg, lamivudine 150 mg, didanosine 200 mg or 125 mg for body weight <60 kg)
Number of subjects: 106
Study 11404532 — intervention group
Group type: COMPARATOR
Intervention: Double drug therapy (zidovudine plus lamivudine)
Number of subjects: 106
Study 11404532 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple drug therapy
Number of subjects: 106
Study 11404532 — intervention group
Group type: COMPARATOR
Intervention: Double drug therapy
Number of subjects: 106
Study 9404926 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose G-CSF (50 microg/m2/day)
Number of subjects: 30
Study 9404926 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose G-CSF (5 microg/kg/day, approximately 200 microg/m2/day)
Number of subjects: 30
Study 9404926 — intervention group
Group type: COMPARATOR
Intervention: Standard-dose G-CSF (5 microg/kg/day)
Number of subjects: 30
Study 8424379 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe energy restriction (SER)
Number of subjects: 30
Study 8424379 — intervention group
Group type: COMPARATOR
Intervention: Moderate energy restriction (MER)
Number of subjects: 30
Study 3307498 — intervention group
Group type: EXPERIMENTAL
Intervention: Disulfiram
Number of subjects: 453
Study 3307498 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 453
Study 31269801 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV risk-reduction intervention (RRI) delivered over 12 weeks focusing on communication, problem-solving, and negotiation skills.
Number of subjects: 30
Study 31269801 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control group (no intervention during the initial 12 weeks).
Number of subjects: 30